TCW — Deck

Trican Well Service · TCW · TSX

Trican is a Calgary-based pure-play pressure pumper that rents frac crews, cementing trucks, and coiled-tubing units to oil and gas producers in Western Canada, charging per-job fees collected on 60–80 day terms.

$4.67
Price
$981M
Market cap
$801M
Revenue (FY25)
21.9%
EBITDA margin
Listed 1996; traded near $0.33 at the March 2020 trough, then compounded to $5.80 at the March 2026 peak before giving back a third in four months to $4.67.
2 · The tension

May 12 resolves the whole debate — a single earnings print decides cycle-turn or cycle-peak.

  • Management just named it. The Q4 2025 MD&A flagged pricing pressure continuing into Q1 2026 and customers "deferring or cancelling" capital programs — the first time that language has appeared since FY2020. WCSB rig count fell from 231 in Q1 2025 to 196 in Q4 2025.
  • The margin hinge is 18%. At a 55% direct-cost base, a 5% pricing cut strips roughly $40M of EBITDA off the $175M FY25 run-rate — collapsing margin from 21.9% toward 16%. Anything below 18% on May 12 confirms pricing has cracked; at or above 21% reopens the compounding story.
  • The tape is already voting. Stock topped at $5.80 in late March, sits 9% below the 50-day and only 3% above the 200-day ($4.51). A weekly close under $4.51 triggers the measured path to $4.02, then $3.21.
One print, four weeks out, settles an argument both sides cite from the same MD&A and the same rig-count fall.
3 · Money picture

Cleanest balance sheet in WCSB pumping at a bottom-quartile multiple.

5.6×
EV / EBITDA 20-yr mean ~9.5×
21.9%
EBITDA margin 4th year in 20–25% band
0.3×
Net debt / EBITDA peers run 0.6–2.5×
8.0%
FCF yield $109M on $981M cap

Margins stabilized at mid-teens for four consecutive years — unusual for a sub-industry whose direct peers (Calfrac 5.5% ROIC, STEP 0%, Precision 0.2%) earn sub-6% through-cycle. Trican's 16.3% ROIC reflects pricing discipline in a basin that consolidated after smaller operators exited. The 5.6× multiple sits above the post-2020 average of 4.8× but well below the 6.5–7.0× fair-cycle anchor; closing that gap needs the FY25 margin band to hold through the Q1 2026 print.

4 · The compounding machine

A buyback, not a business, is what has compounded value here.

  • 52% of the 2017 float retired. Trican has bought back and cancelled 179.2M shares since 2017 at a weighted-average $2.20 — well below today's $4.67 — for roughly $394M. The cumulative NCIB is ex post accretive by about 2.2× invested capital.
  • $70M returned in 2025 alone. $30M dividends plus $40M in buybacks, roughly 9% of the market cap in one year, against $109M of free cash flow. Dividend raised 10% to $0.04/quarter.
  • Per-share, not empire. 86% at-risk CEO pay, zero option grants since 2022, STIP capped with overflow deferred to LTIP. Board chair is an industry operator; a 9% shareholder-director (Coolen, ex-Iron Horse) sits on the capital-return side of every decision.
Per-share economics are what management controls; absolute growth is what the cycle controls. The track record is that they know which is which.
5 · Iron Horse — the wobble

The first acquisition in seven years landed on the wrong side of the oil curve.

Bought: $57M cash plus 33.76M shares — roughly 20% of the pre-deal float — closed August 27, 2025. Pitched at under 3× EBITDA, targeting ~$58M of run-rate EBITDA and billed as immediately accretive with double-digit lifts to EBITDA, FCF, and earnings. Trican-Canada's first M&A since the 2017 Canyon deal.

Missed: Oil cracked four weeks after close. Iron Horse H2 2025 contribution came in at $55M revenue and $1.7M profit; Q4 ran below plan. On the February 20 call, CEO Fedora conceded the ~$58M EBITDA bar will likely be missed in 2026 — a public downgrade of the deal economics versus how it was sold in July.

Price: Net debt swung from −$18M (2024) to +$58M (2025), first non-zero debt since 2021. Share count ticked from 188.9M to 210.8M, reversing 2024's buyback progress. Of FY25's $84M YoY revenue growth, roughly $55M came from Iron Horse — organic growth was low single-digits on a price base that has since cracked.

Counter-cyclical thesis or diluted top-tick — the next two quarters of Iron Horse run-rate settle it.
6 · Off-filing signal

The Q4 call and the tape send different messages than the glossy outlook deck.

  • CFO bought, CEO is thin. CFO Matson bought roughly $95k of stock around the Iron Horse close — a rare positive insider signal. But CEO Fedora owns just 0.48% (~$4.7M), only 1.5× annual comp after five years in the chair — light for a tenured CEO through an up-cycle.
  • Analyst target: $5.51. The post-print sell-side target was raised to $5.51 — roughly 18% above the April 17 close. The DCF mid-point ($5.76) and base-case 6.5× multiple ($5.11) bracket it.
  • MACD is at an 18-month low. Momentum histogram printed its deepest negative bar of the entire window on April 16; RSI fell from 73 to 33 in eleven weeks. Volume is running above the 50-day average in five of the last eight weeks — distribution, not profit-taking.
7 · For & against

Lean cautious — wait for May 12 before the buyback story gets a second chapter.

  • For. A 52%-of-float buyback at $2.20 proves management uses weakness, not conviction, to compound per-share value — and they raised the dividend twice in 2025 while the stock was still below $5.
  • For. At 0.3× net debt to EBITDA and 35× interest coverage, Trican is the only WCSB pumper that can absorb a 2016-style trough without recapitalizing through equity — which is exactly how the competitive set thinned out.
  • Against. Iron Horse already missed its own Q4 numbers, debt went from −$18M to +$58M, and the 20% dilution reversed two years of NCIB progress right as pricing cracked. Cycle-peak ROIC is not through-cycle ROIC.
  • Against. The 200-day ($4.51) is 3% below the tape, MACD at an 18-month low, and the base-case Graham ($4.29) and median-P/S ($4.10) anchors both sit below today's price. The asymmetry is no longer obviously positive.
My view — the Q4 MD&A language is the first to name customer capex cuts since FY2020, and the mechanism (a 5% pricing cut takes $175M EBITDA toward $131M) is specific enough to matter at $4.67. Wait for May 12: a 21%+ margin and an NCIB restart reopens the case; a sub-18% print turns $3.29 from a scenario into a price.

Watchlist to re-rate: Q1 2026 EBITDAS margin on May 12 (18% is the line); whether the NCIB restarts at these $4–5 prices; WCSB rig count trajectory from 196 back toward 220.